Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1733-1738

  Hirose, Takashi ^a   Sugiyama, Tomohide ^a   Kusumoto, Sojiro ^a   Shirai, Takao ^a   Nakashima, Masanao ^a   Yamaoka, Toshimitsu ^a   Okuda, Kentaro ^a   Ogura, Keiichi ^b   Ohnishi, Tsukasa ^a   Ohmori, Tohru ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

Author keywords

Nedaplatin; Non small cell lung cancer; Phase II study; Weekly paclitaxel

Indexed keywords

NEDAPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL;

EID: 67650088347     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18: 317-323, 2007.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell cancer. N Engl J Med 346: 92-98, 2002.
3. Sandler A, Gray R, Perry M, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006. (Pubitemid 44917502)
4. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A and Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung carjcer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784, 2004. (Pubitemid 41103588)
5. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A and Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794, 2004. (Pubitemid 41103589)
6. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH and Miller VA; TRIBUTE Investigator Group.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899, 2005. (Pubitemid 46300205)
7. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM and Von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation trial. J Clin Oncol 25: 1545-1552, 2007. (Pubitemid 46733081)
8. Georgiadis MS, Russell EK, Gazdar AF and Johnson BE: Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 3: 449-454, 1997. (Pubitemid 27158070)
9. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68: 1104-1109, 1993. (Pubitemid 23356660)
10. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R and Taraboletti G: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.
11. Reshkin SJ, Bellizzi A, Cardone RA, Tommasino M, Casavola V and Paradiso A: Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na(+)/H(+) exchanger (NHE) isoform 1 in human breast cancer cells. Clin Cancer Res 9: 2366-2373, 2003.
12. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P and Leone L: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153-158, 1998. (Pubitemid 28041593)
13. Shiratori O, Kanai H and Uchida N (eds.): Recent advances in chemotherapy: Antitumor activity of 254-S, a platinum complex, in rodents. University of Tokyo Press, Tokyo, 1985.
14. Furase K, Fukuoka M, Asamoto H, Niitani H, Kimura I, Sakuma A and Yamaguchi Y: A randomized comparative study of 254-S plus Vindesin (VDS) vs. Cisplatin plus VDS in patients with advanced non-small cell lung cancer. Jpn J Cancer Chemother 19: 1019-1026, 1992 (in Japanese).
15. Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R and Saito H: Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 52: 73-78, 2003. (Pubitemid 36920631)
16. Shirai T, Hirose T, Noda M, Ando K, Ishida H, Hosaka T, Ozawa T, Okuda K, Ohnishi T, Ohmori T, Horichi N and Adachi M: Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small cell lung cancer. Lung Cancer 52: 181-187, 2006.
17. Okuda K, Hirose T, Ishida H, Kusumoto S, Sugiyama T, Ando K, Shirai T, Ohnishi T, Horichi N, Ohmori T and Adachi M: Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 61: 829-835, 2008. (Pubitemid 351302039)
18. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Meta-analysis of randomized clinical trails comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 3852-3859, 2004. (Pubitemid 41079865)
19. Yamada H, Uchida N, Maekawa R and Yoshioka T: Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 172: 17-25, 2001. (Pubitemid 32823468)
20. Koizumi T, Kubo K, Shinozaki S, Koyama S, Amari T, Hayano T, Fujimoto K, Kobayashi T, Sekiguchi M and Sakai R: Pharmacokinetic evaluation of (glycolao-O,O′) diammine platinum (II) in lung lymph in sheep. Jpn J Cancer Res 84: 468-473, 1993. (Pubitemid 23136009)
21. Kelly K, Crowley J, Burn PA Jr., Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB and Gandara DR: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patient with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001.
22. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable P and Tester WJ: Randomized phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated non-small-cell lung cancer. J Clin Oncol 26: 468-473, 2008.
23. Scagliotti GV, Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L and Tonato M: Italian Lung Cancer Project: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-4291, 2002. (Pubitemid 35266288)
24. Schuette W, Blankenburg T, Guschall W, Dittrich I, Schroeder M, Schweisfurth H, Chemaissani A, Schumann C, Dickgreber N, Appel T and Ukena D: Muliticenter randomized trial for stage III/IV non-small-cell lung cancer using every 3-week versus weekly paclitaxel/ carboplatin. Clin Lung Cancer 7: 338-343, 2006.
25. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J and Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998. (Pubitemid 28481632)
26. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman H and Niell HB: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17: 104-109, 2006. (Pubitemid 43033848)
27. Yoshiike F, Koizumi T, Kitaguchi Y Hatayama O, Yasuo M, Sasabayashi M, Wakamatsu H, Fujimoto K and Kubo K: Phase I trial of nedaplatin and paclitaxel for patients with non-small cell lung cancer. J Chemother 17: 550-554, 2005. (Pubitemid 41695603)
28. Sekine I, Nokihara H, Horiike A, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T and Saijo N: Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. Br J Cancer 90: 1152-1158, 2004. (Pubitemid 38496801)